Orchid Pharma Limited (ORCHPHARMA) fundamentals
Orchid Pharma Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ORCHPHARMA (ISIN INE191A01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Orchid Pharma Limited does
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
Valuation and market data
| Last close | ₹1003.05 |
|---|---|
| Market capitalisation | ₹4,888 crore |
| Enterprise value | ₹5,002 crore |
| P/E (TTM) | 0.00 |
| Price to book | 3.86 |
| Price to sales (TTM) | 4.45 |
| Book value per share | ₹260.05 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Nov 02 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,289 crore | ₹35 crore | ₹35 crore | 0.00 |
| Mar 2025 | ₹954 crore | ₹106 crore | ₹106 crore | 20.99 |
| Mar 2024 | ₹850 crore | ₹92 crore | ₹95 crore | 19.59 |
| Mar 2023 | ₹685 crore | ₹55 crore | ₹55 crore | 13.28 |
| Mar 2022 | ₹566 crore | ₹-53 crore | ₹-53 crore | -1.18 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 69.8% |
|---|---|
| Foreign institutions (FII) | 0.8% |
| Mutual funds | 19.9% |
| Other domestic institutions | 0.8% |
| Retail and others | 8.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.